Individuals with generalized anxiety disorder (GAD) who experience ongoing worry, stress, or difficulty managing anxiety symptoms may qualify for a research study evaluating an investigational treatment.
General Anxiety Disorder Study
Age Range:
18 to 74
Gender:
Male and Female
Location:
West Chester, Pennsylvania
About the Study
This research study evaluates RE104, an investigational medication given as a single injection, designed to rapidly reduce anxiety symptoms and potentially provide sustained improvement after one dose.
Qualifications
You May Qualify If:
- Are 18 to 74 years of age
- Have moderate to severe anxiety symptoms
- Are willing and able to attend study visits and follow study procedures
- Have someone available to escort you home after the dosing visit
FEATURED STUDIES
Heart Disease & Inflammation Study
Adults 18 years of age and older with elevated inflammation levels and heart disease or certain health conditions that increase
Heart Failure Prevention Study
Researchers are evaluating an investigational treatment for adults who have type 2 diabetes and cardiovascular disease and may be at
Weight & Wellness Research Study Interest
Researchers are evaluating an investigational oral treatment for adults who are overweight and may be at risk of developing certain
Flu Prevention Study Interest List
Researchers are evaluating an investigational medication that may help prevent the flu in people who are at higher risk of
General Anxiety Disorder Study
Individuals with generalized anxiety disorder (GAD) who experience ongoing worry, stress, or difficulty managing anxiety symptoms may qualify for a
Uncontrolled COPD Study
Individuals with chronic obstructive pulmonary disease (COPD) who continue to experience symptoms or flare-ups despite treatment may qualify for a